Business

Bangladeshi generics company Beximco Pharmaceuticals announced that it has entered into a joint venture with Malaysian pharma company BioCare and said that the first joint project, an MDI manufacturing facility in Seri Iskandar Pharmaceutical Park, Perak, Malaysia, has already received GMP approval from the Malaysian Ministry of Health. Beximco, which will own 30% … [Read more...] about Beximco joint venture with BioCare includes new GMP inhaler facility

Inhaled drug developer Pulmatrix has announced an agreement to sell approximately 2 million shares of its common stock to institutional investors at $2.50 per share in a registered direct offering expected to generate net proceeds of approximately $4.5 million. Closing is expected on February 2, 2017, the company said, and proceeds will be used to pay indebtedness … [Read more...] about Pulmatrix announces $5 million registered direct offering

Altimmune, which is developing intranasal vaccines against influenza and anthrax, is set to merge with vaccine developer PharmAthene, the companies have announced. Altimmune will become a wholly-owned subsidiary of PharmAthene subject to stockholder approval of the all-stock transaction, and the combined company will operate under the name Altimmune. After years … [Read more...] about NasoShield developer Altimmune to merge with PharmAthene

AIR001 developer Mast Therapeutics will merge with AeroVanc and Molgradex developer Savara, the companies have announced. Savara's current management team will lead the combined company, which will be called Savara Inc and which will trade under a new stock ticker symbol. After the merger, current Savara stockholders will own ~76% of the combined company, and current … [Read more...] about Mast Therapeutics to merge with Savara

Satsuma Pharmaceuticals, a spin out from Shin Nippon Biomedical Laboratories (SNBL) has closed a $12 million Series A financing co-led by RA Capital Management and TPG Biotech, the company said. Proceeds will be used to fund development of the company's STS101 dihydroergotamine (DHE) intranasal dry powder for the treatment of migraines. In 2013, SNBL announced … [Read more...] about Satsuma Pharmaceuticals spins out from SNBL to develop intranasal dihydroergotamine

Days after its subsidiary Nicovations cancelled supply agreements with Bespak, British American Tobacco says that it and Kind Consumer "have reached a mutually satisfactory agreement on the financial aspects" on "a new approach to commercialize the Voke nicotine inhaler" in which BAT will return the rights to the inhaler to Kind, "allowing Kind to embrace the full … [Read more...] about BAT returns Voke inhaler rights to Kind Consumer

Vectura and Mundipharma have signed an agreement for the development and commercialization of the VR2076 ICS/LABA/LAMA MDI, Vectura has announced. Skyepharma, which was acquired by Vectura earlier this year, had previously announced a development and commercialization deal for the MDI, then known as SKP-2076, in December 2015. Mundipharma and a "US associated … [Read more...] about Vectura and Mundipharma sign development deal for triple therapy MDI

Horizon Pharma has announced that Quinsair levofloxacin inhalation solution is now available in Canada for the treatment of P. aeruginosa lung infections in adult cystic fibrosis patients. Horizon acquired Quinsair when it acquired Raptor Pharmaceutical company in October 2016. Raptor launched Quinsair in Europe in April 2016. Horizon Pharma VP and General Manager, … [Read more...] about Horizon launches Quinsair inhaled levofloxacin in Canada